Side-effects of opioids in chronic pain treatment

Current Opinion in Anaesthesiology

Volumn 11, Issue 5, 1998, Pages 539-545

  Lawlor, Peter G ^a   Bruera, Eduardo ^a  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; MORPHINE; OPIATE; PETHIDINE;

ALLODYNIA; ANXIETY NEUROSIS; CANCER PAIN; CHRONIC PAIN; DELIRIUM; GASTROINTESTINAL DISEASE; HUMAN; HYPERALGESIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MYOCLONUS; NEUROPSYCHIATRY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SEDATION; SEIZURE; SLEEP DISORDER; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031731399     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-199810000-00016     Document Type: Review

References (92)

1. Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol 1995; 22 (suppl. 3):67-72.
2. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996; 335:1124-1132.
3. World Hearth Organization. Expert Committee Report 1990. Cancer pain relief and palliative care. Technical Series 804. Geneva, Switzerland: World Health Organization; 1990.
4. McQuay HJ. Opioid use in chronic pain. Acta Anaesthesiol Scand 1997; 41:175-183.
5. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990; 5:546-562.
6. World Hearth Organization. Cancer Pain Relief. Geneva, Switzerland; 1986.
7. Clausen TG. International opioid consumption. Acta Anaesthesiol Scand 1997; 41:162-165.
8. De Lima L, Bruera E, Joranson DE, Vanegas G, Cepeda S, Quesada L, et al. Special Report: Opioid availability in Latin America: the Santo Domingo Report. Progress since the Declaration of Florianopolis. J Pain Symptom Manage 1997; 13:213-218.
9. Joranson DE. Availability of opioids for cancer pain: recent trends, asssessment of system barriers, new World Hearth Organization guidelines, and the risk of diversion. J Pain Symptom Manage 1993; 8:353-360.
10. Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet 1993; 341:1075-1076.
11. Sjogren P, Eriksen J. Opioid toxicity. Curr Opin Anaesthesiol 1994; 7:465-469.
12. Pereira J, Bruera E. Emerging neuropsychiatric toxicities of opioids. In: Innovations in drug development, evaluation and use, vol. 5. AG Lipman (editor). New York: The Haworth Press, Inc.; 1997. pp. 3-29.
13. Ripamonti C, Bruera E. CNS adverse effects of opioids in cancer patients. Guidelines for treatment. CNS Drugs 1997; 8:21-37. This is a comprehensive review of central nervous system-related side-effects occurring in cancer patients on opioid therapy. Clinically relevant side-effects are discussed and treatment approaches are outlined.
14. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 1998; 74:5-9.
15. Lipowski ZJ. Update on delirium. Psychiatr Clin North Am 1992; 15:335-346.
16. American Psychiatric Association Diagnostic and Statistics Manual of Mental Disorders. Washington, DC. American Psychiatric Association (APA); 1994.
17. Lawlor P, Walker P, Bruera E, Mitchell S. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 1997; 13:356-361.
18. Portenoy RK. Management of common opioid side effects during long term therapy of cancer pain. Ann Acad Med 1994; 23:160-170.
19. Breitbart W, Bruera E, Chochinov H, Lynch M. A National Cancer Institute of Canada Workshop on symptom control and supportive care in patients with advanced cancer: methodological and administrative issues. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995; 10:131-141.
20. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice patients. J Pain Symptom Manage 1997; 14:157-167.
21. Lawlor P, Gagnon B, Mancini I, Pereira J, Bruera E. The occurrence, causes and outcome of delirium in advanced cancer patients: a prospective study. Presented at the 1st International Conference on Research in Palliative Care: Methodologies and Outcome. Bethesda, MD, 7-9 May 1998. J Pain Symptom Manage 1998; 15:S12.
22. Bruera E, Schoeller T, Montejo G. Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 1992; 48:397-399.
23. Leipzig RM, Goodman H, Gray G, Erle H, Reidenberg MM. Reversible, narcotic-associated mental status impairment in patients with metastatic cancer. Pharmacology 1987; 35:47-54.
24. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989; 39:13-16.
25. Banning A, Sjogren P. Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clin J Pain 1990; 6:91-95.
26. Sjogren P, Banning A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 1989; 39:5-11.
27. Sjogren P, Banning A, Christensen CB, Pedersen O. Continuous reaction time after single dose, long-term oral and epidural opioid administration. Eur J Anaesthesiol 1994; 11:95-100.
28. Clemens M, Regnard C, Appleton T. Alertness, cognition and morphine in patients with advanced cancer. Cancer Treat Rev 1996; 22:451-468.
29. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability in cancer patients receiving long term morphine analgesia. Lancet 1995; 346:667-670.
30. Lorenz J, Beck H, Bromm B. Cognitive performance, mood and experimental pain before and during morphine induced analgesia in patients with chronic non-malignant pain. Pain 1997; 73:369-375.
31. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AI, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998; 15:185-194.
32. Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon A. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for the management of cancer pain. Lancet 1991; 337:465-468. Comment in: Lancet 1991; 337:979.
33. MacDonald N, Der L, Allan S, Champion P. Opioid excitability: the application of alternate opioid therapy. Pain 1993; 53:353-355.
34. Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manage 1997; 14:51-58.
35. Bruera E, Pereira J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain 1997; 69:199-201.
36. Osborne R, Thompson P, Joel SP, Trew D, Patel N, Slevin ML. The activity of morphine-6-glucuronide. Br J Pharmacol 1992; 34:130-138.
37. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990; 47:579-585.
38. Gong QL, Hedner J, Björkman R, Björkman T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48:249-255.
39. Bowsher D. Paradoxical pain: when the metabolites of morphine are in the wrong ratio. BMJ 1993; 306:473-474.
40. Wolff T, Samuelsson H, Hedner T. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain 1996; 68:209-216.
41. Glare PA, Walsh TD, Pippenger CE. Normorphine, a neurotoxic metabolite? Lancet 1990; 335:725-726.
42. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62:259-274.
43. Cherny NI, Foley KM. Nonopioid and opioid analgesic pharmacotherapy of cancer pain. Hematol/Oncol Clin North Am 1996; 10:79-102.
44. Pereira J, Bruera E. Chronic nausea. In: Cachexia-anorexia in cancer patients, Vol. 2. Bruera E, Higginson I (editors). Oxford: Oxford University Press; 1996. pp. 23-27.
45. Hagen NA, Foley KM, Cerbhone DJ, Portendy RK, Inturrisi CE. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 1991; 6:125-128.
46. Kandeel F, Mena I, Chlebowski R. Differential effects of opioids on solid phase gastric emptying in patients with and without cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12:459.
47. Manara L, Bianchetti A. The central and peripheral influence of opioids on gastrointestinal propulsion. Ann Rev Pharmacol Toxicol 1985; 75:249-273.
48. Bruera E, Belzile M, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled release metaclopramide (CRM) and placebo for chronic nausea and dyspepsia (CND) of advanced cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17:50a.
49. Bruera E, MacEachern T, Spachynski K, LeGatt D, MacDonald RN, Babul N, et al. Comparison of the efficacy, safety and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 1994; 74:3204-3211.
50. Bruera E, Suarez-Almazor M, Velasco A, Bertolino M, MacDonald SM, Hanson J. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage 1994; 9:515-519.
51. Mancini I, Hanson J, Bruera E. Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study [abstract]. 1st International Conference on Research in Palliative Care: Methodologies and Outcomes, Bethesda, MD, 7-9 May 1998. J Pain Symptom Manage 1998; 15:16.1.
52. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998; 15:168-175.
53. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage 1997; 13:254-261.
54. Foley KM. Opioids. Neurol Clin 1993; 11:503-522.
55. Bruera E, Lawlor P. Cancer pain management. Acta Anaesthesiol Scand 1997; 41:146-153.
56. Bruera E, Schoeller T, Wenk R, MacEachern T, Marcelino S, Suarez-Almazor M, Hanson J. A prospective multi-center assessment of the Edmonton Staging System for cancer pain. J Pain Symptom Manage 1995; 10:348-355.
57. Lipowski ZJ. Acute confusional states. New York: Oxford University Press; 1990.
58. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration and opiate rotation. J Pain Symptom Manage 1995; 10:287-291.
59. Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, Reidenberg HM. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1997; 86:738-741.
60. Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturrisi CE, Reidenberg HM. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13:180-185.
61. Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. Am J Psychiatry 1987; 144:1062-1065.
62. Parkinson SK, Bailey SL, Little WL, Mueller JB. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 1990; 72:743-745.
63. Steinberg RB, Gilman DE, Johnson IIIF. Acute toxic delirium in a patient using transdermal fentanyl. Anesth Analg 1992; 75:1014-1016.
64. Sjogren P, Jensen H-N, Jensen T-S. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59:313-316.
65. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation (OR) for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10:378-384.
66. Paix A, Coleman A, Lees J, Gribbon J, Brookbank H, Thorne D, Ashby M. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995; 63:263-269.
67. Moss JH. Anileridine-induced delirium. J Pain Symptom Manage 1995; 10:318-320.
68. Maddocks I, Somogyi A, Abbot F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996; 12:182-189.
69. Fitzgibbon DR, Ready LB. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high dose morphine. Pain 1997; 73:259-261.
70. Krames ES, Gershow J, Glassberg A, Renefick T, Lyons A, Taylor P, Wilkie D. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer 1985; 56:696-702.
71. De Conno F, Caraceni A, Mantini C, Spoldie E, Salvetti H, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47:337-339.
72. Eisele JH, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992; 49:231-232.
73. Sjogren P, Dragsted L. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993; 37:780-782.
74. Caraceni A, Martini C, De Conno F, Ventafridda V. Organic brain syndromes and opioid administration for cancer pain. J Pain Symptom Manage 1994; 9:527-533.
75. Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anaesthesiol 1997; 9:146-148.
76. Fallon M. Opioid rotation: does it have a role? Palliat Med 1997; 11:177-179.
77. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996; 78:852-857.
78. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997; 72:79-85.
79. Lawlor PG, Turner KS, Hanson J, Bruera E. Dose ratio between morphine and methadone in patients with cancer pain. Cancer 1998; 82:1167-1173.
80. Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992; 48:163-166.
81. Breitbart W, Chochinov HM, Passik S. Psychiatric aspects of palliative care. In: Oxford textbook of palliative medicine. Doyle D, Hanks G, MacDonald N (editors). Oxford: Oxford University Press; 1998. pp. 933-954.
82. Nunez-Olarte JM. Opioid-induced myoclonus. Eur J Palliat Care 1996; 2:146-150.
83. Jasinski DR. Tolerance and dependence to opiates. Acta Anaesthesiol Scand 1997; 41:184-186.
84. Pasternak GW, Kolesnikov YA, Babey A-M. Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Neuropsychopharmacology 1995; 13:309-313.
85. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995; 187:165-168.
86. Sallerin-Caute B, Lazorthes Y, Deguine O, Frances B, Verdie J-C, Charlet J-P, Bastide R. Does intrathecal morphine in the treatment of cancer pain induce the development of tolerance? Neurosurgery 1998; 42:44-50.
87. Moulin DE, Line GSF, Pasternak GW. Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain 1988; 33:233-239.
88. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated. Pain 1997; 73:151-157.
89. Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage 1996; 11:163-171.
90. Porter J, Kink H. Addiction rate in patients treated with narcotics. N Engl J Med 1980; 302:123.
91. Chapman CR, Hill HF. Prolonged morphine self administration and addiction liability. Cancer 1989; 63:1636-1644.
92. Wall PD. The generation of yet another myth on the use of narcotics. Pain 1997; 73:121-122.